Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease

Fabrizio Stocchi, Laura Fabbri, Laszlo Vecsei, Anna Krygowska-Wajs, Piero Alessandro Monici Preti, Stefano A. Ruggieri

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

A possible cause of motor fluctuations in patients with Parkinson disease is the erratic drug absorption. In a randomized double-blind double-dummy study of melevodopa (levodopa methyl ester), a highly soluble levodopa pro-drug plus carbidopa (CHF 1512) was compared to a standard formulation of levodopa/carbidopa (LD/CD) in 74 fluctuating Parkinson disease patients. The first afternoon, LD/CD tablet was substituted with an equimolar dose of CHF 1512. The study lasted 4 weeks and was followed by an 8-week (optional) open phase. The primary efficacy variable was latency to "on." Patients randomized to receive CHF 1512 had a significative shorter latency to "on" than those randomized to LD/CD and a similar "on" duration. The safety profile of CHF 1512 was also comparable with LD/CD.

Original languageEnglish
Pages (from-to)18-24
Number of pages7
JournalClinical Neuropharmacology
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 1 2007

Keywords

  • Afternoon "off" period
  • Carbidopa
  • Latency to "on"
  • Levodopa
  • Levodopa methyl ester
  • Melevodopa
  • Motor fluctuation
  • Parkinson disease

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease'. Together they form a unique fingerprint.

  • Cite this